Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma

N Engl J Med. 2006 Jun 8;354(23):2514-5. doi: 10.1056/NEJMc053129.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Celiac Disease / complications
  • Celiac Disease / drug therapy*
  • Celiac Disease / pathology
  • Duodenal Neoplasms / prevention & control
  • Duodenum / pathology*
  • Female
  • Humans
  • Lymphoma, T-Cell / prevention & control*
  • Middle Aged

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab